Exogenous Recombinant Adiponectin Improves Survival in Experimental Abdominal Sepsis by Salman, Bulent et al.
Bacterial	sepsis	is	the	major	cause	of	mortality	and	morbid-
ity	 among	 patients	 (1).	The	 conventional	 therapy	 for	 sepsis	
includes	maintenance	of	tissue	perfusion	and	treatment	of	in-
fections.	Several	pathophysiological	pathways	that	have	been	
determined	to	be	involved	in	sepsis	involve	an	imbalance	be-
tween	 inflammatory	and	 immune	responses;	 these	pathways	
were	targeted.	Cytokines,	especially	tumor	necrosis	factor-α	
(TNF-α)	 and	 interleukin	 (IL)-6,	 together	 with	 oxygen	 free	
radicals,	 are	 believed	 to	 be	 the	 responsible	 factors	 in	 tissue	
injury	 that	precedes	multiple	organ	dysfunction	with	activa-
tion	of	 the	endothelial	 system	and	vascular	dysfunction	 (2).	
One	of	the	molecules	that	increases	macrophage	binding	and	
activation	is	intracellular	adhesion	molecule	(ICAM-1),	which	
is	 closely	 linked	 to	 the	 inflammatory	 response.	 Beside	 the	
cytokines	and	adhesion	molecules	 that	play	a	role	 in	 the	 in-
flammatory	response,	macrophage	migration	inhibitory	factor	
(MIF),	which	plays	a	role	in	native	immunity,	plays	a	crucial	
role	in	sepsis	mechanisms	as	a	proinflammatory	cytokine	(3).	
Proinflammatory	 cytokine	 expression	 is	 increased	 by	 MIF,	
which	is	related	to	mortality	in	sepsis.	From	this	point	of	view,	
the	removal	or	neutralisation	of	inflammatory	cytokines	and	
ICAM	molecules	and	depression	of	MIF	is	one	approach	 to	
sepsis	treatment.
Several	 inflammatory	cytokines,	especially	TNF-α,	act	by	
using	a	nuclear	factor	(NF)-kB	pathway	(4).	Activation	of	NF-
kB	leads	to	the	secretion	of	several	inflammatory	cytokines,	
chemokines,	enzymes,	and	adhesion	molecules.	Inhibition	of	
NF-kB	activity	might	therefore	decelerate	inflammation.
Adiponectin	 (APN),	 an	 adipocyte-derived	 protein,	 shows	
its	 anti-inflammatory	 properties	 by	 antagonizing	 the	 effects	
of	TNF-α	 (5).	Also,	 it	 has	 been	 shown	 that	APN	neutraliz-
es	endotoxin	activities	 in	vitro	and	slows	the	progression	of	
polymicrobial	sepsis	in	rats	(6).	In	experimental	and	clinical	
studies,	a	negative	corelation	between	plasma	APN	levels	and	
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plasma	TNF-α	levels	in	sepsis	has	been	shown	(7,	8).	Howev-
er,	details	of	the	effects	and	intracellular	mechanisms	of	action	
of	APN	remain	obscure.	For	this	reason,	we	hypothesize	that	
administration	of	APN	in	experimental	 intrabdominal	sepsis	
could	influence	the	anti-inflammatory	effect.	The	aim	of	this	
study	 was	 to	 evaluate	 the	 effects	 of	APN	 on	 inflammatory	
cytokines,	ICAM-1,	MIF,	and	NF-kB	and	survival	in	a	cecal	
ligation	and	puncture	model.
MATERIAL AND METHODS
Animals
All	procedures	were	performed	according	to	the	guidelines	
of	 the	Care	and	Use	of	Experimental	Animals	and	were	ap-
proved	by	the	Local	Ethics	Commitee.	A	total	of	90	rats	were	
kept	at	21ºC	with	a	12-h	light	and	dark	cycle	for	1	week	before	
the	 experiment.	All	 rats	were	 fasted	 overnight	 for	 12	 hours	
with	access	to	water	ad	libitum	prior	to	the	induction	of	sepsis.
Experimental protocol
The	rats	were	randomly	divided	into	3	groups:	Sham	group	
(n=30),	Control	 group	 (n=30),	 and	APN	group	 (n=30).	An-
aesthetized	(50	mg/kg	ketamine	i.m;	ketalar	(10%	Ketamidor,	
Richter	Pharma	Co	KG,	Wels,	Austria)	rats	underwent	midline	
laparotomy.	We	isolated	the	cecum	and	than	ligated	1cm	be-
low	the	ileocecal	valve	using	3/0	silk	suture.	The	cecum	was	
punctured	two	times	with	a	22-gauge	needle.	Intraperitoneal	
recombinant	adiponectin	(2	µg/kg)	(Biovision,	CA,	USA)	was	
given	to	the	rats	in	the	APN	group.	The	rats	in	the	sham	group	
underwent	laparotomy	only.	Before	closure	of	the	abdomen,	
3	mL/100	g	of	saline	was	 injected	 into	 the	 intraperitoneum.	
Every	3	hours,	rats	in	the	control	group	received	1	mL	of	intra-
peritoneal	saline,	while	rats	in	the	APN	group	received	intra-
peritoneal	APN	(2	µg/kg).	On	the	6th	hour	after	the	cecum	liga-
tion	and	puncture	(CLP),	10	rats	in	the	control	group	and	10	
rats	in	the	APN	group	were	sacrified	under	ketamine	anaesthe-
sia.	Ten	rats	in	sham	group	were	sacrified	at	the	3rd	hour	after	
the	laparotomy.	Ten	more	rats	in	the	control	and	APN	groups	
were	 sacrified	 at	 the	 24th	 hour	 after	 CLP.	 Cecum	 necrosis	
was	seen	in	all	rats	in	the	laparotomy	group	at	the	3rd	and	24th	
hours.	The	degree	of	 intraperitoneal	adhesion	was	classified	
as	either:	0:	no	adhesion,	1:	adhesion	in	the	lower	abdomen,	2:	
adhesion	in	the	upper	abdomen.	The	adhesions	were	evaluated	
during	 the	 laparotomy	at	 the	24th	hour.	Blood	samples	were	
taken	from	all	rats	through	the	inferior	vena	cava.	Centrifuga-
tion	at	3000	rpm	for	10	minutes	at	4ºC	was	performed	in	order	
to	seperate	the	plasma.	The	plasma	was	stored	at	-80ºC.	We	
measured	plasma	IL-6,	TNF-α,	IL-10,	soluble	ICAM-1,	and	
macrophage	inhibitory	factor	using	a	specific	enzyme-linked	
immunosorbent	 assay	 (ELISA)	 kit	 (Biosource	 International,	
Camarillo,	CA,	USA).	The	NF-κB	activity	was	measured	us-
ing	the	method	described	by	Arnalich	F	et	al.	(9).
The	remaining	30	rat	were	kept	under	standard	conditions,	
allowed	free	access	to	food	and	water	ad	libitum	and	followed	
until	death	or	for	a	period	of	6	days.	The	time	from	the	end	
of	CLP	to	death	was	accepted	as	the	survival	time	of	the	rats.
Data analysis
Data	from	the	study	are	presented	as	mean±SD	and	were	ana-
lysed	by	Statistical	Package	for	the	Social	Sciences	(SPSS)	ver-
sion	14.00	(SPSS,	Chicago,	IL,	USA).	A	one-way	analysis	of	
variance	(ANOVA)	with	postHoc	Scheffy	was	used	for	group	
comparisons.	A	bivariant	Pearson	correlation	test	was	used	for	
group	correlations.	The	level	of	statistical	significance	was	set	
at	p<0.05.	The	survival	rate	was	measured	by	the	Kaplan-Meier	
method	and	compared	using	the	log	rank	test.
RESULTS
The	mean	 levels	of	data	at	 the	3rd	and	24th	hours	 for	each	
group	and	the	means	of	all	data	in	the	groups	were	evaluated.	
The	levels	are	given	in	Table	1.
	 TNF-α	(pg/mL)	 IL-6	(pg/mL)	 IL-10	(pg/mL)	 ICAM-1	(ng/mL)	 MIF	(pg/mL)	 NF-kB	(%)
Sham	(n=30)	 4.5±1.2	 92±11	 174±8.4	 137.2±6.3	 156.5±34.2	 4
Control	(n=30)
3rd	hour	(n=10)	 26.4±4.5	 254±9	 94.8±9	 245.5±7.4	 941.6±42.2	 43
24th	hour	(n=10)	 37.5±6.5	 323.5±15	 59.5±8.1	 313.4±5.4	 837.2±32.2	 35
Overall	(n=20)	 31.5±6.1	 298±24	 89.2±9.8	 279.4±6.1	 889.4±36.4	 40
APN	(n=30)
3rd	hour	(n=10)	 12.3±3.5	 112.4±5.5	 165.4±4.5	 163.4±3.2	 803.7±25.2	 12
24th	hour	(n=10)	 18.5±4.2	 174.5±6.2	 133.5±4.1	 202.4±4.3	 682.1±32.1	 8
Overall	(n=20)	 15.5±3.2	 154.2±18	 158±24.4	 182.9±3.6	 742.9±28.1	 10
TNF-α:	Tumor	necrosis	factor-	α;	IL:	interleukin;	ICAM:	Intracellular	adhesion	molecule;	MIF:	macrophage	migration	inhibitory	factor;	NF-κB:	nuclear	factor	kappa	B;	
pg:	picogram;	ng:	nanogram;	mL:	mililitre
TABLE 1. The	mean	levels	of	TNF-α,	IL-6,	IL-10,	ICAM-1	and	MIF	and	the	activity	of	NF-kB	and	overall	means	are	given	at	the	3rd	and	24th	hours
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There	were	 significant	 differences	 between	 groups	 re-
garding	 the	overall	mean	 levels	of	TNF-α,	 IL-6,	 ICAM-
1	and	MIF	 (p<0.05)	 (Figure	1).	The	overall	mean	 levels	
were	 significantly	 increased	 in	 the	 control	 group	 when	
compared	 with	 the	APN	 and	 the	 sham	 group	 (p<0.05).	
On	the	other	hand,	the	levels	in	the	APN	group	were	sig-
nificantly	higher	than	in	the	sham	group	but	significantly	
lower	than	in	the	control	group	(p<0.05).	When	the	mean	
levels	 of	 TNF-α,	 IL-6,	 and	 ICAM-1	 at	 the	 3rd	 and	 24th	
hours	 were	 compared,	 the	 levels	 significantly	 increased	
with	 time	 (p<0.05).	 However,	 the	 increases	 in	 TNF-α	
(r=0.022),	 IL-6	 (r=0.034),	 and	 ICAM-1	 (r=0.028)	 levels	
in	the	control	group	were	not	correlated	with	those	in	the	
APN	group.	The	increases	in	the	APN	group	were	smaller	
than	in	the	control	group.
The	levels	of	IL-10	in	the	control	group	were	significantly	
lower	than	in	the	sham	and	APN	groups	(p<0.05).	On	the	other	
hand,	the	difference	between	the	level	of	IL-10	in	the	APN	and	
control	 groups	was	not	 significant.	The	 levels	 of	 IL-10	 and	
MIF	decreased	at	the	24th	hour.	While	the	difference	between	
the	levels	at	the	3rd	and	24th	hours	was	significant	for	IL-10,	
the	difference	was	not	 significant	 for	MIF.	There	were	 also	
significant	 differences	 in	 the	 survival	 rates	between	groups.	
In	 our	 study,	 NF-kB	 activity	was	 significantly	 increased	 in	
the	control	group	compared	with	 the	sham	group.	However,	
NF-kB	 activity	was	 decreased	 in	 the	APN	 group	 compared	
with	 the	control	group.	On	 the	other	hand,	NF-kB	activities	
between	 the	3rd	 and	24th	 hours	did	not	 show	any	 significant	
changes.
The	mean	intraabdominal	adhesion	scores	of	the	sham,	con-
trol	and	APN	groups	were	0.4±0.6,	1.7±0.4,	and	1.2±0.4,	re-
spectively.	The	mean	adhesion	score	 in	 the	APN	group	was	
significantly	higher	than	the	mean	adhesion	score	of	the	con-
FIG. 1. a-f. The levels of TNF-α, IL-6, IL-10, ICAM-1 and MIF at the 3rd and 24th hours. The overall means are also given. P values of the 
comparisons were pointed by the α, b, and μ. NF-κB activity in the different groups, given as percentages. TNF-α levels in the groups at the 
3rd and 24th hours. β: p=0.01, α: p=0.001, μ: p=0.03 (a). IL-6 levels in the groups at the 3rd and 24th hours. β: p=0.01, α: p=0.001, μ: p=0.03 (b). 
ICAM-1 levels in the groups at the 3rd and 24th hours. β: p=0.02, α: p=0.001, μ: p=0.04 (c). NF-kB activity in the groups at the 3rd and 24th hours. 
β: p=0.67, α: p=0.001, μ: p=0.56 (d). MIF levels in the groups at the 3rd and 24th hours. β: p=0.122, α: p=0.01, µ: p=0.09 (e). IL-10 levels in the 
groups at the 3rd and 24th hours. β: p=0.01, α: p=0.005, μ: p=0.03, #: p=0.001 (f)
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FIG. 2. Differences in survival curves produced by the administration 
of APN. The survival rates after CLP in the sham, APN and control 
groups. Differences between the survival rate s in each group were 
analyzed by the log-rank test. Administration of APN significantly 
increased survival time when the APN group was compared with the 
control group (p<0.001)
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trol	 group.	At	 the	 end	 of	 a	 six-day	 follow-up,	 survival	was	
found	 to	be	 improved	 in	 the	APN	group	compared	with	 the	
control	group	(p<0.001;	Figure	2).
DISCUSSION
In	our	study,	we	found	that	the	administration	of	intraperito-
neal	APN	decreased	inflammatory	cytokines,	increased	an	anti-
inflammatory	cytokine,	and	decreased	intrabdominal	adhesions	
in	an	experimental	intrabdominal	sepsis	model,	and	we	demon-
strated	that	APN	supplementation	might	be	a	promising	therapy	
for	sepsis.	As	the	CLP	septic	model	mimics	clinically	observed	
sepsis	with	the	same	inflammatory	and	pathological	sequences	
including	 Lipopolysaccharide	 (LPS)	 mediated	 reactions,	 we	
used	the	CLP	model	in	order	to	evaluate	the	effects	of	APN.
Adiponectin	has	been	studied	for	its	role	in	glucose	metabo-
lism	and	it	has	been	noted	that	APN	levels	are	decreased	in	
obese	 patients,	 patients	 suffering	 from	 coronary	 artery	 dis-
ease,	and	diabetic	patients	(10).	APN	also	has	important	rela-
tionships	in	inflammatory	reactions.	There	have	been	several	
studies	showing	that	APN	is	an	anti-inflammatory	substance	
(5,	 8).	 In	 in	 vitro	 studies,	 it	was	 shown	 that	 administration	
of	APN	to	cultured	macrophages	supressed	the	macrophages	
phagocytosis	 and	 LPS-induced	 TNF-α	 production.	Also,	 it	
was	demonstrated	that	the	human	recombinant	APN	directly	
bound	LPS	and	suppressed	limulus	amoebocyte	lysate	activity	
in	vitro	(6,	11).	Similarly,	our	experimental	study	showed	that	
the	APN	 treatment	 decreased	TNF-α,	 IL-6,	 and	MIF	 levels	
while	APN	increased	the	levels	of	IL-10.
It	was	 further	shown	 that	APN	deficiency	 led	 to	 increased	
levels	 of	 plasma	TNF-α	 and	 IL-6	 in	 an	 experimental	 sepsis	
model	obtained	by	CLP.	Decreased	APN	led	to	increased	sus-
ceptibility	 to	 polymicrobial	 sepsis	with	 higher	mortality	 and	
increased	TNF-α	and	IL-6	levels	(8).	It	was	seen	that	while	the	
levels	of	APN	decreased,	the	plasma	TNF-α	levels	increased,	
along	with	the	lessening	of	sepsis.	In	our	study,	as	sepsis	pro-
gressed,	TNF-	α	and	IL-6	levels	increased	in	the	control	group,	
but	the	increase	was	significantly	lower	and	slower	in	the	APN	
group.	These	results	showed	that	APN	interacts	by	neutraliz-
ing	LPS.	Our	study	showed	that	APN	decreased	the	inflamma-
tory	 response	and	also	decelerated	 the	progression	of	 sepsis.	
Low	levels	of	APN	seen	in	sepsis	lead	to	excessive	amounts	of	
IL-6	and	TNF-α,	which	suppress	APN	production	in	the	adi-
pose	tissue	(12).	The	endotoxin,	which	had	been	released	after	
the	onset	of	intra-abdominal	sepsis,	was	neutralized	by	several	
proteins	 such	 as	 albumin	 and	 LPS-binding	 proteins,	 but	 the	
remainder	of	the	proteins	activated	macrophages	and	induced	
inflammatory	mediators.	A	lack	of	APN	has	also	been	shown	to	
increase	the	amount	of	endotoxin	in	CLP	models	(8).	Further-
more,	a	key	anti-inflammatory	cytokine	(IL-10)	was	decreased	
in	sepsis	 in	our	study,	but	 the	APN	inhibited	 the	decrease	 in	
IL-10.	This	 result	 further	 supports	 the	 anti-inflammatory	 ef-
fects	of	APN.	The	neutralization	of	 free	endotoxins	by	APN	
might	diminish	inflammatory	cytokine	levels,	as	a	deficiency	
in	APN	led	to	an	increased	inflammatory	response	and	mortal-
ity.	Local	administration	of	APN	in	abdominal	sepsis	produced	
beneficial	effects	 in	our	 study.	However,	 intravenous	admin-
istration	of	APN	should	be	 the	subject	of	future	studies.	De-
creased	adhesion	in	APN	is	a	sign	of	a	decreased	inflammatory	
response	in	the	abdomen.	This	is	also	another	subject	for	future	
studies	on	the	local	antiinflamatory	effects	of	APN.
In	previous	studies,	several	factors	were	shown	to	decrease	
the	APN	 levels	 in	 sepsis.	 Endothelial	 injury,	 high	 levels	 of	
catecholamines,	glucocorticoids,	and	 IL-6	 levels	are	 seen	 in	
polymicrobial	 sepsis	 and	 all	 suppressed	 production	 of	APN	
(13).	For	 this	 reason,	 it	 is	 reasonable	 to	 administer	APN.	 It	
was	observed	that	Rosiglitazone	augmented	plasma	APN	lev-
els	when	administered	before	the	sepsis.	In	this	way,	a	signifi-
cantly	decreased	mortality	rate	was	achieved	in	an	experimen-
tal	model	 (14).	 In	 our	 study,	 administration	 of	APN,	which	
is	 different	 from	 the	 previous	 studies,	 improved	 survival.	
Administration	of	APN,	just	with	the	onset	of	sepsis	with	re-
petitive	doses	during	sepsis,	resulted	in	a	beneficial	effect	not	
only	on	local	adhesions	but	also	on	sepsis.	This	finding	shows	
us	that	the	benefits	of	APN	are	not	only	expressed	before	the	
induction	of	sepsis	but	also	during	the	progression	of	sepsis.	
APN	supplementation	with	repetitive	doses	might	be	an	en-
couraging	treatment	for	patients	with	low	levels	of	APN	or	for	
patients	who	are	in	the	early	phases	of	sepsis.
Besides	 its	 effects	 on	LPS,	APN	affects	 endothelial	 func-
tion.	Impaired	endothelial	function	and	leukocyte-endothelial	
interactions	 have	 been	 demonstrated	 in	APN-deficient	mice	
(15).	Furthermore,	APN	deficiency	 resulted	 in	 increased	 re-
cruitment	of	neutophils	in	the	peritoneal	cavity	and	more	en-
dothelial	 cell	 adhesion	molecules	 (ICMA-1,	VCAM-1)	 and	
exaggrated	 cytokine	 production	 in	 a	 peritonitis	model	 (14).	
The	 circulating	neutrophils	were	 attached	 to	 the	 endothelial	
cells	 and	 became	 activated	 with	 the	 help	 of	 adhesion	mol-
ecules,	 including	 ICAM-1.	 Adhesion	 molecules	 (ICAM-1,	
VCAM-1)	were	 found	 to	 be	 increased	 in	 sepsis	 (16).	Mor-
phological	changes	with	the	activation	of	inflammatory	cells	
lead	to	further	inflammatory	reactions.	The	effects	of	APN	on	
monocytes	 decreased	 phagocytic	 activity,	 decreased	 adher-
ence,	 and	 decreased	 lipid	 content.	All	 of	 these	 results	 pro-
duced	a	decreased	inflammatory	response.	By	administering	
APN,	we	might	favor	its	anti-inflammatory	effects	on	mono-
cytes	as	well.	In	our	study,	ICAM-1	levels	increased	signifi-
cantly	with	 sepsis	 progression	 and	APN	decelerated	 the	 in-
crease.	Our	results	support	the	beneficial	effects	of	APN	over	
endothelial	 function	 in	sepsis.	The	result	of	 the	 influence	of	
APN	on	 endothelium	 in	 our	 study	was	 decreased	 adhesion.	
This	shows	us	that	APN	also	has	a	local	antiinflammatory	ef-
fect	on	endothelium.
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Migration	 inhibitory	 factor	 activates	 T-cells	 and	 macro-
phages	in	response	to	sepsis.	Although	it	is	a	response	to	sep-
sis,	increased	levels	of	MIF	are	closely	related	to	the	severity	
of	sepsis.	In	early	phases,	MIF	levels	are	prognostic	factors	for	
the	 severity	of	 sepsis	 (17).	 Improved	 survival	was	achieved	
by	neutralizing	MIF	in	an	experimental	sepsis	model.	In	our	
study,	APN	 decreased	MIF	 levels	when	 compared	with	 the	
control	group.	Both	ICAM-1	and	MIF	are	related	 to	NF-kB	
activity.	This	 suggested	 that	 the	 effect	 of	APN	 is	 related	 to	
NF-kB	activity.	In	previous	studies,	it	was	shown	that	primary	
APN	receptors	led	to	the	activation	of	several	pathways,	 in-
cluding	AMP	kinase	and	p38	mitogen-activated	kinase	(18).	
On	 the	 other	 hand,	 non-receptor-mediated	 events	were	 also	
noted	in	association	with	high	circulating	levels	of	APN	(14).	
Although	 the	 effects	 of	APN	 on	 intracellular	 pathways	 are	
not	 yet	 clear,	 this	 field	 is	 another	 subject	 of	 research.	 The	
decreased	NF-kB	activity	seen	 in	our	 study	 is	probably	due	
to	decreased	stimulatory	effects.	In	addition	to	these	results,	
administration	of	APN	increased	survival	rates	significantly.
Although	 further	 studies	 are	 required	 to	 explain	 the	 intr-
aractions	between	APN	and	sepsis-related	changes,	this	study	
showd	that	APN	has	both	local	and	systemic	anti-inflammatory	
effects	in	an	experimental	sepsis	model.	Administration	of	APN	
in	experimental	abdominal	sepsis	decreased	inflammatory	cy-
tokines,	decreased	intrabdominal	adhesions	and	improved	sur-
vival	with	its	anti-inflammatory	effects.	This	finding	might	be	
promising	for	the	treatment	of	intrabdominal	sepsis.
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